Autoimmune movement disorders

Testing to ensure the best outcomes for every patient

With differing causes and a variety of symptoms, autoimmune movement disorders and phenomena, which can be ataxic, hypokinetic, or hyperkinetic, are often associated with antibody biomarkers. Detection of these clues provides insights that direct individualized treatment protocols aligned with symptom severity, type of antibody discovered, and the presence and absence of cancer.

movement disorders Test menu

Movement Disorders

Our comprehensive autoimmune movement disorders panel is continuously updated to include newly discovered biomarkers and uses advanced testing approaches to detect actionable antibodies. Test results can help guide appropriate treatment, which can include oncologic therapy, immunotherapy, and symptomatic therapy.

Key testing

Advantages

  • Continuously updated to include clinically actionable antibodies most relevant to patients suspected of having autoimmune movement disorders.
  • Includes several antibodies found only at Mayo Clinic Laboratories: Septin 5, Septin 7, and TRIM46.
  • Advanced methodology provides optimized sensitivity and specificity.
  • Can guide search for cancer and/or treatment selection.

Highlights


Stiff-person spectrum disorders

While varied in presentation, the unifying clinical and electrophysiologic characteristic of stiff-person spectrum disorders — which include classical stiff-person syndrome, focal stiff-person forms (stiff-limb and stiff-trunk), and a severe encephalomyelitic form known as progressive encephalomyelitis with rigidity and myoclonus (PERM) — is central nervous system hyperexcitability. The most common IgG biomarker detected in the stiff-person spectrum is GAD65 antibody; however, glycine receptor (GlyRα1), DPPX, and amphiphysin antibodies are also found. Since each biomarker is associated with a unique prognosis and treatment plan, antibody detection is integral to enabling the best therapeutic response.

Key testing

Advantages

  • Exclusively available at Mayo Clinic Laboratories.
  • Evaluates for the presence of GAD65, GlyRα1, DPPX, and amphiphysin antibodies, which are the four known antibodies associated with the disorder.
  • Enables faster diagnosis.
  • Guides treatment selection.
  • Can direct a search for cancer.

Highlights


Ma2-directed illness

Mayo Clinic Laboratories has optimized Ma2 antibody detection through the development of an innovative, enzyme-linked immunosorbent assay (ELISA). Developed by an integrated team of Mayo Clinic neurologists and autoimmune neurology testing experts, our Ma2 ELISA evaluation provides increased sensitivity for improved antibody detection. Ma2 testing used in conjunction with autoimmune/paraneoplastic encephalopathy and movement disorder panel evaluations provides the most comprehensive, up-to-date coverage of autoimmune/paraneoplastic antibodies available, equipping providers with assurance that nothing was missed.

Key testing

Advantages

  • Uses ELISA to detect Ma2 antibodies.
  • Offers increased sensitivity for improved antibody detection.
  • Helps direct search for associated cancers.
  • Facilitates treatment to halt the destructive immune response and potentially reverse symptoms.

Additional testing

Ma2 testing used in conjunction with autoimmune/paraneoplastic encephalopathy and movement disorder panel evaluations provides the most comprehensive, up-to-date coverage of autoimmune/paraneoplastic antibodies available, equipping providers with assurance that nothing was missed. Because 32% of Ma2 patients present with excessive daytime sleepiness, assessing for the neuropeptide orexin can assist in confirming diagnosis.

Highlights

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.